Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Abstract:

:L-Dopa-induced dyskinesias (LID) are the most common adverse effects of long-term dopaminergic therapy in Parkinson's disease (PD). However, the exact mechanisms underlying dyskinesia are still unclear. For a long time, nigrostriatal degeneration and pulsatile stimulation of striatal postsynaptic receptors have been highlighted as the key factors for the development of LID. In recent years, PD models have revealed a wide range of non-dopaminergic neurotransmitter systems involved in pre- and postsynaptic changes and thereby contributing to the pathophysiology of LID. In the current review, we focus on therapeutic LID targets, mainly based on agents acting on dopaminergic, glutamatergic, serotoninergic, adrenergic, and cholinergic systems. Despite a large number of clinical trials, currently only amantadine and, to a lesser extent, clozapine are being used as effective strategies in the treatment of LID in clinical settings. Thus, in the second part of the article, we review the placebo-controlled trials on LID treatment in order to disentangle the changing scenario of drug development. Promising results include the extension of L-dopa action without inducing LID of the novel monoamine oxidase B- and glutamate-release inhibitor safinamide; however, this had no obvious effect on existing LID. Others, like the metabotropic glutamate-receptor antagonist AFQ056, showed promising results in some of the studies; however, confirmation is still lacking. Thus, to date, strategies of continuous dopaminergic stimulation seem the most promising to prevent or ameliorate LID. The success of future therapeutic strategies once moderate to severe LID occur will depend on the translation from preclinical experimental models into clinical practice in a bidirectional process.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Schaeffer E,Pilotto A,Berg D

doi

10.1007/s40263-014-0205-z

subject

Has Abstract

pub_date

2014-12-01 00:00:00

pages

1155-84

issue

12

eissn

1172-7047

issn

1179-1934

journal_volume

28

pub_type

杂志文章,评审
  • Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

    abstract:BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0358-z

    authors: Üçok A,Çıkrıkçılı U,Ergül C,Tabak Ö,Salaj A,Karabulut S,Correll CU

    更新日期:2016-10-01 00:00:00

  • Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment.

    abstract::Disability, characterised by the loss of ability to perform activities of daily living (ADL), is a defining feature of dementia that results in growing caregiver burden and the eventual need for alternative care or nursing home placement. Functional decline in patients with dementia can also result from causes other t...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418130-00003

    authors: Desai AK,Grossberg GT,Sheth DN

    更新日期:2004-01-01 00:00:00

  • Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.

    abstract::Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological an...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-016-0393-9

    authors: Swart T,Hurley MJ

    更新日期:2016-12-01 00:00:00

  • Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study.

    abstract:PURPOSE:To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. METHODS:Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist circumference, systolic and diasto...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0229-z

    authors: Verrotti A,Parisi P,Agostinelli S,Loiacono G,Marra F,Coppola G,Pisani LR,Gorgone G,Striano P,Pisani F,Belcastro V

    更新日期:2015-02-01 00:00:00

  • Treatment Options for Narcolepsy.

    abstract::Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy ab...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-016-0337-4

    authors: Barateau L,Lopez R,Dauvilliers Y

    更新日期:2016-05-01 00:00:00

  • Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?

    abstract::As in all patient populations, epilepsy is common in pregnant women. Consequently, approximately 1 in 200 pregnancies is exposed to antiepileptic drugs (AEDs). Although exposure to AEDs in utero has been associated with an increased risk of major fetal malformations, most women with epilepsy require medication through...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620100-00001

    authors: Adab N

    更新日期:2006-01-01 00:00:00

  • Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.

    abstract:BACKGROUND:Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monomethyl fumarate and are...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00700-0

    authors: Naismith RT,Wundes A,Ziemssen T,Jasinska E,Freedman MS,Lembo AJ,Selmaj K,Bidollari I,Chen H,Hanna J,Leigh-Pemberton R,Lopez-Bresnahan M,Lyons J,Miller C,Rezendes D,Wolinsky JS,EVOLVE-MS-2 Study Group.

    更新日期:2020-02-01 00:00:00

  • The new generation of GABA enhancers. Potential in the treatment of epilepsy.

    abstract::gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115050-00001

    authors: Czuczwar SJ,Patsalos PN

    更新日期:2001-01-01 00:00:00

  • Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.

    abstract:BACKGROUND:Dravet syndrome (DS) is one of the most severe forms of drug-resistant epilepsy and available interventions fail to control seizures in most patients. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs with a distinctive chemical structure and mechanism of action. OBJECTIVE:The aim of this...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00708-6

    authors: Lattanzi S,Brigo F,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M

    更新日期:2020-03-01 00:00:00

  • Treatment of epileptic encephalopathies.

    abstract::Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0041-6

    authors: McTague A,Cross JH

    更新日期:2013-03-01 00:00:00

  • Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

    abstract:BACKGROUND:Several small studies have shown beneficial effects of ondansetron, a serotonin 5-HT(3) receptor antagonist, in the treatment of obsessive-compulsive disorder (OCD). The efficacy of other 5-HT(3) receptor antagonists in patients with OCD is still unclear. Granisetron does not alter cytochrome P450 activity a...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.2165/11635850-000000000-00000

    authors: Askari N,Moin M,Sanati M,Tajdini M,Hosseini SM,Modabbernia A,Najand B,Salimi S,Tabrizi M,Ashrafi M,Hajiaghaee R,Akhondzadeh S

    更新日期:2012-10-01 00:00:00

  • Nusinersen: A Review in 5q Spinal Muscular Atrophy.

    abstract::Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disorder most commonly caused by a deletion or mutation in the survival motor neuron 1 (SMN1) gene, which leads to insufficient levels of survival motor neuron (SMN) protein. In such patients, SMN protein production relies on the SMN2 gene. Nusi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0545-1

    authors: Hoy SM

    更新日期:2018-07-01 00:00:00

  • Topiramate: as monotherapy in newly diagnosed epilepsy.

    abstract::Topiramate is an antiepileptic drug that has a broad spectrum of antiseizure effects, which appear to be the result of several neurostabilising pharmacological mechanisms. These include blockade of ion channels, potentiation of GABA neuroinhibition and glutamate receptor antagonism at non-NMDA receptors, as well as mi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317130-00007

    authors: Waugh J,Goa KL

    更新日期:2003-01-01 00:00:00

  • Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period.

    abstract:INTRODUCTION:The use of methylphenidate for the treatment of attention deficit-hyperactivity disorder (ADHD) has increased dramatically in the past decade in some countries in Europe and North America. In response to a public debate in Israel, several Knesset members introduced a legislative initiative that aims to lim...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200317120-00005

    authors: Fogelman Y,Vinker S,Guy N,Kahan E

    更新日期:2003-01-01 00:00:00

  • Cognitive effects of statin medications.

    abstract::The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Admi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0147-5

    authors: Kelley BJ,Glasser S

    更新日期:2014-05-01 00:00:00

  • Mitoxantrone: a review of its use in multiple sclerosis.

    abstract::Mitoxantrone (Novantrone), a synthetic anthracenedione derivative, is an antineoplastic, immunomodulatory agent. Its presumed mechanism of action in patients with multiple sclerosis (MS) is via immunomodulatory mechanisms, although these remain to be fully elucidated. Intravenous mitoxantrone treatment improved neurol...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418060-00010

    authors: Scott LJ,Figgitt DP

    更新日期:2004-01-01 00:00:00

  • Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

    abstract::This review focuses on current information about luteal phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a luteal phase administration regimen reduces the exp...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418070-00004

    authors: Freeman EW

    更新日期:2004-01-01 00:00:00

  • Mixed Anxiety and Depression : Diagnosis and Treatment Options.

    abstract::Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199809040-00003

    authors: Bakish D,Habib R,Hooper CL

    更新日期:1998-04-01 00:00:00

  • Spotlight on oxcarbazepine in epilepsy.

    abstract::Oxcarbazepine (Trileptal, Timox) is structurally related to carbamazepine and has anticonvulsant activity. Studies suggest that the anticonvulsant activity of oxcarbazepine is mediated via the blocking of neuronal ion channels. In patients aged <18 years, the efficacy of oxcarbazepine monotherapy was similar to that o...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200418010-00006

    authors: Bang LM,Goa KL

    更新日期:2004-01-01 00:00:00

  • Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.

    abstract:SYNOPSIS:Mirtazapine is a tetracyclic antidepressant with a novel mechanism of action; it increases noradrenergic and serotonergic neurotransmission via blockade of central α2-adrenergic auto- and heteroreceptors. The increased release of serotonin (5-hydroxytryptamine; 5-HT) stimulates serotonin 5-HT1 receptors becaus...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199605050-00007

    authors: Davis R,Wilde MI

    更新日期:1996-05-01 00:00:00

  • Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

    abstract:BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-013-0049-y

    authors: Sutter R,Marsch S,Rüegg S

    更新日期:2013-04-01 00:00:00

  • Affective disorders in patients with HIV infection: impact of antiretroviral therapy.

    abstract::At the beginning of the AIDS pandemic, affective disorders (such as depressed mood) were seen in a considerable number of HIV-1-infected individuals. These disorders were a result of the poor physical condition of the patients, brain involvement by the virus (e.g. encephalopathy) or a reaction to disadvantageous livin...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620060-00005

    authors: Arendt G

    更新日期:2006-01-01 00:00:00

  • Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

    abstract::NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...

    journal_title:CNS drugs

    pub_type: 已发布勘误

    doi:10.1007/s40263-018-0595-4

    authors: Papadopoulos D,Mitsikostas DD

    更新日期:2019-01-01 00:00:00

  • Pharmacological management of treatment-resistant obsessive-compulsive disorder.

    abstract::Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11587860-000000000-00000

    authors: Abudy A,Juven-Wetzler A,Zohar J

    更新日期:2011-07-01 00:00:00

  • Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.

    abstract::Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-co...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00702-y

    authors: Elsayed NA,Yamamoto KM,Froehlich TE

    更新日期:2020-04-01 00:00:00

  • The star systems: overview and use in determining antiepileptic drug choice.

    abstract::An explosion in antiepileptic drug (AED) therapy began in the 1990s with the licensing of 9 new chemical entities and more to come. Important differences between AEDs may not be detected by regulatory trials, which are designed to satisfy licensing requirements and often diverge considerably from everyday clinical pra...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115010-00001

    authors: Brodie MJ,Kwan P

    更新日期:2001-01-01 00:00:00

  • Subacute sclerosing panencephalitis : diagnosis and drug treatment options.

    abstract::Subacute sclerosing panencephalitis (SSPE) is a chronic progressive, usually fatal disease of uncertain pathogenesis that is associated with the presence of mutant measles virus in the CNS. The diagnosis is based on clinical criteria and an elevated titre of measles antibodies in the CSF. Electroencephalography, imagi...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199707020-00003

    authors: Anlar B

    更新日期:1997-02-01 00:00:00

  • Female hypoactive sexual desire disorder: epidemiology, diagnosis and treatment.

    abstract::Female hypoactive sexual desire disorder (HSDD) may occur in up to one-third of adult women in the US. The essential feature of female HSDD is a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The evaluation of female HSDD generally requ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216110-00003

    authors: Warnock JJ

    更新日期:2002-01-01 00:00:00

  • Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses.

    abstract::The neuronal ceroid lipofuscinoses comprise a group of neurodegenerative lysosomal storage disorders caused by mutations in at least 13 different genes and primarily affect the brain and the retina of children or young adults. The disorders are characterized by progressive neurological deterioration with dementia, epi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00620-8

    authors: Kohlschütter A,Schulz A,Bartsch U,Storch S

    更新日期:2019-04-01 00:00:00

  • Pharmacotherapy for Friedreich ataxia.

    abstract::Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923030-00003

    authors: Tsou AY,Friedman LS,Wilson RB,Lynch DR

    更新日期:2009-01-01 00:00:00